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Genome scans of bipolar disorder (BPD) have not produced consistent evidence for linkage. The rank-based genome
scan meta-analysis (GSMA) method was applied to 18 BPD genome scan data sets in an effort to identify regions
with significant support for linkage in the combined data. The two primary analyses considered available linkage
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data for “very narrow” (i.e., BP-I and schizoaffective disorder–BP) and “narrow” (i.e., adding BP-II disorder)
disease models, with the ranks weighted for sample size. A “broad” model (i.e., adding recurrent major depression)
and unweighted analyses were also performed. No region achieved genomewide statistical significance by several
simulation-based criteria. The most significant P values (!.01) were observed on chromosomes 9p22.3-21.1 (very
narrow), 10q11.21-22.1 (very narrow), and 14q24.1-32.12 (narrow). Nominally significant P values were observed
in adjacent bins on chromosomes 9p and 18p-q, across all three disease models on chromosomes 14q and 18p-q,
and across two models on chromosome 8q. Relatively few BPD pedigrees have been studied under narrow disease
models relative to the schizophrenia GSMA data set, which produced more significant results. There was no overlap
of the highest-ranked regions for the two disorders. The present results for the very narrow model are promising
but suggest that more and larger data sets are needed. Alternatively, linkage might be detected in certain populations
or subsets of pedigrees. The narrow and broad data sets had considerable power, according to simulation studies,
but did not produce more highly significant evidence for linkage. We note that meta-analysis can sometimes provide
support for linkage but cannot disprove linkage in any candidate region.
Introduction
Bipolar disorder (BPD; loci MAFD1 [MIM 125480] and
MAFD2 [MIM 309200]) is a chronic psychiatric dis-
order with a worldwide lifetime prevalence of 0.5%–
1.5% and a predominantly genetic etiology, based on
twin-study data (Craddock and Jones 1999; Baron
2002). The disorder is characterized by episodes of ma-
nia, with elated or irritable-angry mood and symptoms
like pressured speech, racing thoughts, grandiose ideas,
increased energy, and reckless behavior, alternating with
more normal periods and, in most cases, with episodes
of depression. Numerous studies have investigated link-
age to BPD over the past 2 decades. Early reports sug-
gestive of linkage led to a focus on regions of chro-
mosome 11 (Egeland et al. 1987), the X chromosome
(Baron et al. 1987), and chromosome 18 (Berrettini et
al. 1994). Many whole-genome scans have been pub-
lished, with the most highly positive results receiving
support in some but not most other studies.
This lack of agreement among studies could be a false-
negative result due to inadequate power. Even the larger
available BPD genome scan data sets would not reliably
detect a locus associated with a relative risk to siblings
(lsibs) much less than 1.5 (Craddock et al. 1995; Hauser
et al. 1996), so that loci of modest effect could produce
inconsistent and weak evidence for linkage with variable
peak locations (Roberts et al. 1999). Alternatively,
many reported results could be false positives. Lander
and Kruglyak (1995) noted that, for any large set of
genome scans, several studies can produce positive re-
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sults in the same regions by chance, particularly when
multiple models are tested in most studies. Finally, some
of the BPD findings could be true positives that cannot
easily be replicated, because of substantial heterogeneity
in the loci underlying BPD susceptibility across samples
and across families within samples, a point to which we
return below.
Meta-analysis represents one strategy for determining
the significance of findings from a set of related studies.
Meta-analysis of genome scans presents numerous meth-
odological difficulties, because of the use of diverse phe-
notypic and transmission models, linkage analysis meth-
ods, marker maps and map densities, sample sizes,
pedigree structures, and ethnic backgrounds. Here we
apply the genome scan meta-analysis (GSMA) approach
(Wise et al. 1999) to all known genome scans for BPD
with 20 affected cases, to determine whether statistical
support might be achieved for any chromosomal regions.
The first article in this series (Levinson et al. 2003 [in
this issue]) described the GSMA method in greater detail,
including a simulation study of the method’s power to
detect linkage in data sets resembling the available BPD
and schizophrenia scans.
Previous attempts at meta-analysis have included a
multiple scan probability (MSP) analysis (Badner and
Gershon 2002), which combines P values across scans
in regions with clusters of positive scores after adjusting
for the size of the region, and a preliminary GSMA
(Segurado and Gill 2001). Both of these analyses were
limited to published data. Differences between GSMA
and MSP were discussed in the first article in this series
(Levinson et al. 2003 [in this issue]). The GSMA pre-
sented here includes studies that were not available to
Badner and Gershon (2002) and excludes some smaller
studies that they included (see the “Discussion” section
for further details); our analysis also includes data pro-
vided by the investigators for every marker in each scan,
whereas the MSP used only published data (from studies
that presented data for all nominally significant regions)
and substituted P values of .5 or 1.0 for missing data
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points. By including only complete whole-genome data
from each scan, the present analysis may be expected
to avoid two problems inherent in publication bias: in-
vestigators tend to present their most positive results,
as well as weakly positive results that seem to confirm
others’ findings, which could inflate meta-analysis re-
sults in those regions; and, conversely, GSMA can detect
significant cross-study results for regions that are
weakly positive in many studies but not sufficiently pos-
itive to have been presented as “one of the best results”
in any study.
A number of decisions were required to perform this
GSMA. One is related to diagnoses. Family study data
demonstrate that a number of major mood disorders
coaggregate in families of probands with BPD, including
BP-I disorder (severely dysfunctional manic episodes
with or without depressive episodes), schizoaffective–
bipolar type (SAB; BP-I with periods of persistent de-
lusions or hallucinations after remission of mood epi-
sodes), BP-II (recurrent depression with milder manias),
recurrent major depression, single-episode depression,
and milder mood swings (cyclothymia). Because it is
not known which phenotypic definition best reflects the
underlying genetics of the disorder, many investigators
have performed linkage analyses designating different
combinations of diagnoses as “affected.” To preserve
statistical power, we selected two primary phenotypic
models for the GSMA, but we analyzed two additional
broader models that are of interest to many investiga-
tors in the field. We did not divide the analyses by any
other sample characteristic such as ethnicity.
A second decision was related to sample size. The
number of genotyped affected cases in the available
studies ranged from 424 to 11. As discussed in the first
article in this series (Levinson et al. 2003 [in this issue]),
GSMA is best suited to detect loci that influence disease
susceptibility in many or all samples. It was not expected
to be appropriate for revealing susceptibility loci under
a classical locus heterogeneity model, in which a single
extended pedigree might have the greatest power to de-
tect linkage. Therefore, we excluded from the primary
analyses those scans with !20 affected cases; these were
not considered to contribute any additional power to
detect linkage by GSMA and represented the extreme
of the observed distribution of sample sizes.
Finally, we analyzed each phenotypic model with
and without a weighting factor for sample size
( , the square root of the number ofN[affected cases]
genotyped affected cases), which simulation studies
demonstrated will increase power when the genetic ef-
fect of a locus is similar across samples. Thus, we con-
sidered our primary analyses to be the weighted anal-
yses of models 1 and 2 (defined below).
Material and Methods
Data Collection
Genome scans in BPD, either published or unpub-
lished, were identified via literature databases, confer-
ence presentations, and personal contact with research-
ers in the field. Each group was contacted to secure their
collaboration and to obtain the full list of markers used
and genomewide linkage scores, if these had not been
published. Six genome scan reports that included pedi-
grees from the Old Order Amish (OOA) sample (Detera-
Wadleigh et al. 1994; Gerhard et al. 1994; Ginns et al.
1996; LaBuda et al. 1996; Polymeropoulos and Schaffer
1996; Berrettini et al. 1997) were excluded, because of
sample overlap, in favor of the study that included OOA
data and had the largest overall number of affected in-
dividuals (Detera-Wadleigh et al. 1999). An additional
four scans (Blackwood et al. 1996; Adams et al. 1998;
Radhakrishna et al. 2001; Ewald et al. 2002) had !20
genotyped affected cases and were excluded from pri-
mary analyses; a secondary analysis including these four
scans, without weighting for sample size, did not reveal
any additional findings (details available upon request).
Table 1 shows the list of 18 included scans and diag-
nostic details. These 18 genome scans are from 16 re-
search groups, and 12 of the scan analyses used here
have been published or are in press.
After examining the diagnostic schemes used in these
18 studies, we selected two primary models for GSMA:
model 1 (“very narrow”), including as affected either
BP-I cases or BP-I and SAB cases; and model 2 (“nar-
row”), including BP-I, SAB, and cases judged by the
original investigators to meet current Diagnostic and
Statistical Manual (DSM)–IV criteria for BP-II. We felt
that the primary analyses should focus on BPDs, and
there were too few scans with analyses of the very nar-
row model for us to be comfortable limiting the primary
analyses to those data; therefore, we focused on these
two models. Nine studies included linkage analyses con-
sistent with our model 1, with a total of 347 pedigrees
and 948 genotyped cases. Fourteen studies included link-
age analyses consistent with model 2 (512 pedigrees,
1,733 cases). Among these 14 were 6 studies that had
analyzed both models 1 and 2; 3 studies with only a
model 1 analysis, which was therefore also included in
our model 2; and 5 studies with an analysis under model
2 but not model 1.
Secondary analyses were also performed under a
“broad” disease model (model 3, adding recurrent major
depressive disorder [MDD]; 593 pedigrees, 2,437 cases),
which has been of interest to a majority of investigators
because MDD is the most common disorder in families
with BPD. Note that we included in the model 3 analysis
several studies that included a small proportion of cases
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with additional, broader diagnoses (see table 1), but we
excluded studies whose broad model included a large
proportion of cases with other diagnoses. We also ap-
plied a “very broad” model (model 4, adding single-
episode major depression and cyclothymic disorder; 617
pedigrees, 2,589 cases); results did not reveal any ad-
ditional significant findings and are not presented here
but are available upon request. Table 1 lists the sample
sizes under each disease model; those for models 1 and
2 were small compared with the schizophrenia analysis
(1,208 pedigrees, 2,945 cases) reported in the previous
article in this series (Lewis et al. 2003 [in this issue]).
The linkage statistics used by each study are detailed
in table 1. Research groups were asked to indicate their
primary linkage statistic if several were applied, and this
was preferentially used for ranking. In most cases, para-
metric single-point LOD scores had been computed un-
der two to five transmission models, and we selected the
most significant of these scores (i.e., maximized across
models) as the score for each marker. Other linkage
scores included were multipoint nonparametric tests, in-
cluding the maximum LOD score (MLS), for likelihood-
based affected-sibling-pair (ASP) analysis, or nonpara-
metric linkage (NPL) analysis.
The selected studies were consistent in that they
achieved reasonably even marker coverage of the ge-
nome, used well-established linkage statistical methods,
diagnosed mood disorders on the basis of modern di-
agnostic instruments and criteria, and included predom-
inantly European-ancestry subjects; however, the studies
did vary in sample size, evenness of marker spacing, the
number of linkage analyses that were applied, com-
munity-based versus more ethnically homogeneous sam-
ples, and the typical size of pedigrees.
GSMA
Meta-analysis was performed as described by Wise et
al. (1999) and in the first two articles of this series (Lev-
inson et al. 2003 [in this issue]; Lewis et al. 2003 [in
this issue]). Terminology is summarized in appendix A.
In brief, the genome was divided into 120 30-cM bins
defined by markers from the Ge´ne´thon map (CEPH-
Ge´ne´thon Integrated Map Web site). The average bin
width on the Marshfield map (Center for Medical Ge-
netics Web site) was 29.1 cM. These boundary markers
and their Marshfield locations are shown in figures 1
and 2. Each marker from each study was placed within
one of these bins, on the basis of its location on the
Ge´ne´thon, Marshfield, or Southampton (Genetic Loca-
tion Database Web site) maps or the human genome map
(NCBI Home Page). For each study in a given analysis,
the maximum linkage score (or minimum P value) was
selected within each bin, and the bins were assigned a
rank (Rstudy) in ascending order (“1” designates the bin
with the most significant result). Negative or zero scores
were treated as a set of ties and given the average rank
for the set (e.g., if there were 20 such scores, all were
ranked 110.5). The average rank (Ravg) across studies
was then computed for each bin. For the weighted anal-
ysis, each Rstudy value was then multiplied by its study’s
weight ( , divided by the mean of thisN[affected cases]
value over all studies), as discussed in the first article in
this series (Levinson et al. 2003 [in this issue]). Two
pointwise P values were determined by permutation
(5,000 permutations per analysis): PAvgRnk and Pord, as
defined in appendix A.
Results
Data for 22 genome scans were collected, and 18 were
selected for analysis under models 1–3, as discussed
above (table 1). For these 18 studies, an average of 404.2
(SD 122.9) markers were tested per scan, or 3.37 (SD
1.02) per 30-cM bin. Of the 18 scans, 13 had markers
in all bins, 4 had no markers in 1–3 bins, and 1 older
scan (Utah) had no markers in 19 bins. Linkage results
for missing bins were extrapolated as the average of
surrounding bins. Bins on chromosomes 5, 18, 21, and
22 were covered by 14.6 markers per study, a potential
confounding factor that could not be eliminated, be-
cause, for some studies, the available analyses included
both “screening” markers and those included to test
these candidate regions.
The power of these data sets to detect linkage at var-
ious thresholds was studied as described in detail in the
first article in this series (Levinson et al. 2003 [in this
issue]). Empirical significance thresholds are summa-
rized in appendix A. When there were 10 linked bins
in the genome with a populationwide lsibs of 1.3 for
each locus, the mean number of bins achieving P !
was 0.4 for model 1 and 2.34 for model 2..000417
The power to detect any one locus associated with a
lsibs of 1.15 at was 0.49 for model 1 and 0.77P ! .05
for model 2, averaged across simulated conditions. The
most powerful empirical index of linkage was the ob-
servation of both PAvgRnk and —for example,P ! .05ord
with 10 linked bins in the genome, for , al p 1.3sibs
mean of 4.54 linked bins would achieve this for model
1, and a mean of 8.43 would achieve this for model 2;
or, for , 1.53 and 4.68 bins, respectively.l p 1.15sibs
Figures 1 and 2 summarize the ranked data for each
study for models 1 and 2 and show the average ranks
for each bin for the weighted analysis and its place in
the order of average ranks. The markers that define the
bin boundaries are shown, along with their locations
on the Marshfield map. For clarity, the Rstudy values have
been divided into eight ranges, with “1” representing
ranks 1–5, “2” representing ranks 6–10, etc., as shown
in the legend at the bottom of each figure.
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Figure 1 Individual study and weighted average ranks by bin (model 1). The following are shown: within-study ranks (Rstudy) grouped
as shown in the legend; the average rank (Ravg) for each bin across studies (low values are best), weighted proportional to N(affected cases)
for each study; and the overall place of each bin in ascending order of average ranks (the lowest/best average rank is first-place). Average ranks
with significant PAvgRnk values are highlighted above the columns (black for , gray for ). Tied ranks sometimes resultedP ! .01 P ! .05AvgRnk AvgRnk
in uneven numbers of bins in some groupings, particularly for lower ranks when there were many zero or negative scores. Marshfield (“Mfd”)
locations are shown for the marker at the distal boundary of each bin. Bin boundaries were selected at ∼30-cM spacing on the Ge´ne´thon map;
mean bin width is 29.1 cM on the Marshfield map. Peds p number of pedigrees; Aff p number of genotyped affected cases. See table 1 for
the references associated with each study.
Table 2 shows PAvgRnk and Pord values, for all bins that
achieved in each of these analyses, in as-P ! 0.1AvgRnk
cending overall order. Table 3 shows the same data in
a different format, to illustrate patterns across models:
all bins are listed that achieved under anyP ! .05AvgRnk
of models 1–3 (weighted or unweighted). PAvgRnk values
!.1 are shown, to illustrate whether a bin tended to
achieve lower ranks even under those models in which
a nominal level of significance was not observed. Note
that these analyses are nonindependent—that is, the
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Figure 2 Individual study and weighted average ranks by bin (model 2) (see fig. 1 for explanation)
broader models include the pedigrees from the narrower
models.
No bin reached a genomewide level of significance
(PAvgRnk) in any analysis, and none of the aggregate cri-
teria for linkage, established in the simulation studies
described in the first article in this series (Levinson et
al. 2003 [in this issue]), were met here: in simulated
data, !5% of unlinked GSMA replicates had 11 bins
that achieved by-bin P values !.05; here, the maximum
number of such values was 9 for model 1–weighted and
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Table 2
PAvgRnk and Pord Values for Models 1–3
PLACE
WEIGHTED ANALYSES UNWEIGHTED ANALYSES
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Bin PAvgRnk Pord Bin PAvgRnk Pord Bin PAvgRnk Pord Bin PAvgRnk Pord Bin PAvgRnk Pord Bin PAvgRnk Pord
1 9.2 .006 .497 14.3 .003 .309 14.3 .006 .544 9.2 .009 .685 2.6 .014 .829 14.2 .011 .751
2 10.3 .008 .267 18.2 .013 .478 18.2 .015 .557 1.4 .016 .583 14.2 .016 .605 18.2 .018 .647
3 1.4 .013 .191 2.6 .036 .841 8.6 .037 .850 19.4 .021 .465 14.3 .017 .334 18.3 .019 .406
4 19.4 .017 .144 8.1 .044 .809 7.6 .043 .803 18.1 .038 .698 18.3 .023 .294 11.3 .025 .355
5 9.3 .026 .195 8.6 .045 .672 18.3 .048 .727 10.3 .046 .685 18.2 .027 .209 14.3 .040 .552
6 17.2 .031 .143 5.6 .051 .588 11.3 .054 .658 18.2 .057 .719 5.1 .038 .293 20.1 .045 .456
7 18.2 .031 .057 18.3 .061 .631 20.1 .058 .572 18.3 .059 .595 1.8 .041 .203 21.2 .052 .454
8 18.1 .033 .026 5.1 .065 .547 14.2 .059 .420 5.5 .062 .468 21.2 .042 .107 7.5 .056 .357
9 14.3 .043 .049 21.2 .075 .582 12.4 .064 .354 17.2 .070 .469 3.6 .047 .088 2.6 .056 .214
10 18.3 .055 .091 7.6 .079 .483 21.2 .071 .333 1.8 .070 .325 8.1 .049 .047 1.8 .057 .124
11 6.4 .060 .070 9.3 .080 .342 5.6 .073 .230 9.3 .073 .236 7.5 .059 .065 12.4 .059 .074
12 10.2 .075 .153 14.2 .100 .572 11.1 .079 .212 20.4 .083 .269 8.6 .069 .081 7.6 .059 .036
13 18.4 .082 .138 2.6 .082 .151 12.3 .091 .259 20.4 .074 .067 8.6 .064 .024
14 12.4 .094 .200 9.3 .085 .102 3.4 .092 .170 5.6 .080 .060 20.4 .093 .194
15 5.1 .097 .140 7.5 .095 .117 11.3 .085 .051
16 18.4 .097 .070 9.2 .087 .029
17 2.9 .091 .021
NOTE.—Shown are PAvgRnk and Pord values for all bins with PAvgRnk values !.1 in each analysis, sorted by their overall place in the order of
average ranks for that analysis. P values !.05 and the associated bin labels are shown in boldface italic type.
10 for model 2–unweighted. Also, !5% of unlinked
GSMA replicates had five or more bins that achieved
both PAvgRnk and ; this was not observed in anyP ! .05ord
of the BPD analyses. Finally, !5% of unlinked GSMA
replicates had four or more bins with amongP ! .05ord
the bins with the 10 best average ranks; no BPD analysis
had more than two such bins.
The simulation studies also suggest that, among those
bins with nominally significant PAvgRnk values, those that
also achieve nominally significant Pord values are the most
likely to be linked. In the model 1–weighted analysis, this
was observed for bins 18.1 ( ; )P p .033 P p .026AvgRnk ord
and 14.3 ( ; ). However, these PP p .043 P p .049AvgRnk ord
values do not meet genomewide levels of significance.
We also performed an exploratory GSMA (not shown
in tables 2 and 3) under model 3 for the nine studies
that had no model 1 analysis, since these represented
an independent model 3 data set. PAvgRnk values !.01
were observed for bins 14.2 ( ) and 8.6P p .0025AvgRnk
( ), and was observed forP p .0046 P ! .05AvgRnk AvgRnk
bins 12.4, 11.3, 18.2, 8.5, 20.1, and 9.6 (for which Pord
was also !.05). Thus, no new striking evidence for link-
age was observed, and the regions of interest were sim-
ilar to other analyses, with the addition of chromosomes
9q and 12q.
Finally, to determine whether the placement of bin
boundaries was having a critical effect on results, ad-
jacent bins were combined into 60-cM bins, for the two
possible combinations (e.g., for chromosome 1, bins
12, 34, etc.; and then 23, etc.), for models 1 and
2 (weighted and unweighted). More highly significant
P values were not observed. Regions of interest were
the same, with two exceptions. For model 2 (weighted
and unweighted), bins 7.5 and 7.6 (7q31.1-qter) and
bins 9.2 and 9.3 now achieved , suggestingP ! .05AvgRnk
that a different placement of bins might have produced
nominally significant average ranks in 30-cM bins sur-
rounding the boundaries between these two pairs of
markers (148.1 cM on chromosome 7 and 53.6 cM on
chromosome 9).
Additional data are available at the University of
Pennsylvania Web site listed in the “Electronic-Database
Information” section, including tables of summed ranks
(weighted and unweighted) for each sample and scat-
terplots of average ranks, for models 1–4.
Discussion
We have conducted a rank-based meta-analysis of ge-
nome scans for BPD, incorporating data from all known
nonoverlapping studies with 120 affected cases, to in-
vestigate the combined evidence for linkage across stud-
ies. The rank-based nature of the analysis and the strin-
gency in selection of studies should ensure that the
meta-analysis is not biased by statistical methodology
or by the nature of the individual samples, although it
remains possible that it was confounded by typing of
additional markers in well-known candidate regions.
Previous meta-analyses (Segurado and Gill 2001;
Badner and Gershon 2002) have used only published
data. Badner and Gershon (2002) used the MSP
method, based on P values, which identified regions of
chromosomes 13q (at 79 cM; bin 13.3 here) and 22q
(at 36 cM; bin 22.2 here) as being likely to contain BPD
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Table 3
Patterns of Significance across Models
BIN
MARSHFIELD
LOCATION
(BEGIN–END)
(cM)
CYTOGENETIC
POSITION
PAvgRnk
a
Weighted Unweighted
Model
1
Model
2
Model
3
Model
1
Model
2
Model
3
1.4 83.07–113.69 1p32.1-q31.1 !.05 !.05
1.8 201.58–231.11 1q31-q32 !.1 !.05 !.1
2.6 128.41–154.48 2q22.1-q23.3 !.05 !.1 !.05
3.6 146.6–173.34 3q22.1-q25.31 !.05
5.1 0–31.78 5pter-p15.1 !.1 !.1 !.05
7.6 122.48–148.11 7q34-qter !.1 !.05 !.1
8.1 148.11–190.0 8pter-p22 !.05 !.05b
8.6 137.92–167.9 8q24.21-qter !.05 !.05 !.1 !.1
9.2 27.32–53.6 9p22.3-p21.1 !.01 !.01 !.1
9.3 53.6–84.9 9p21.1-q21.32 !.05 !.1 !.1 !.1
9.6 109.9–136.5 9q33.3-9qter
10.3 62.23–91.13 10q11.21-q22.1 !.01 !.05
11.3 47.06–72.82 11p13-q13.3 !.1 !.1 !.05
12.4 82.12–109.47 12q15-q23.2
14.2 40.11–74.96 14q13.1-q24.1 !.1 !.05 !.05
14.3 74.96–105 14q24.1-q32.12 !.05b !.01 !.01 !.05 !.05
17.2 25.14–63.62 17p12-q21.33 !.05 !.1
18.1 0–24.08 18pter-p11 !.05b !.05
18.2 24.08–62.84 18p11-q12.3 !.05 !.05 !.05 !.1 !.05 !.05
18.3 62.84–96.48 18q12.3-q22.1 !.1 !.1 !.05 !.1 !.05 !.05
19.4 75.41–105.0 19q13.33-qter !.05 !.05
20.1 0–21.15 20pter-p12.3 !.1 !.05
21.2 25.26–57.8 21q21.3-qter !.1 !.05 !.1
a Listed are all bins with PAvgRnk ! .05 under any disease model. PAvgRnk values ! .1 are shown only
to indicate how consistently a bin achieved lower ranks across models.
b Indicates that a bin with also had .P ! .05 P ! .05AvgRnk ord
susceptibility loci. The data sets only partially over-
lap—that is, their analysis included four studies that
contributed identical data to the present meta-analyses,
three that were not included here, and four for which
there were apparently differences in the data used (de-
tails available on request). Further, for the present anal-
ysis, the investigators provided data for all markers in
each scan if these were not listed in the publication.
Badner and Gershon (2002) also combined data from
different diagnostic models. Thus, it is possible that dif-
ferences in the data sets account for the differences in
results. This interpretation is supported by the fact that
a preliminary GSMA of a similar set of published data
(Segurado and Gill 2001) also observed its most sig-
nificant results on chromosomes 13q and 22q. These
results are not supported by the present analysis, which
was based on a larger number of data sets, complete
genome scan data, and separate analyses of each di-
agnostic model. Linkage might be present in these
regions in some samples, or it might be present too
weakly to detect consistently.
In the absence of genomewide significant findings, we
note here the patterns of results that may be of interest
to BPD researchers. The most significant PAvgRnk values
in the primary weighted analyses of models 1 and 2
were observed for bin 14.3 ( ; modelP p .003AvgRnk
2), bin 9.2 ( ; model 1), and bin 10.3P p .006AvgRnk
( ; model 1). Two other trends of possibleP p .008AvgRnk
interest include (1) observing low average ranks for a
bin across diagnostic models, which would be consistent
with family study data suggesting a BPD spectrum; and
(2) observing low average ranks for adjacent bins, which
was common in the simulation studies in the presence
of linkage. In the primary analyses, bins 9.2 and 9.3
achieved and , respectively, andP ! .01 P ! .05AvgRnk AvgRnk
bins 18.1 and 18.2 achieved (all underP ! .05AvgRnk
model 1). Bins 14.3 and 18.2 achieved P  .05AvgRnk
across models 1–3 (weighted analyses), bin 8.6 achieved
this for models 2 and 3, and bins 9.2 and 9.3 achieved
this for models 1 and 2 when they were combined into
a single 60-cM bin. Thus, the present analyses provide
some support for the hypothesis that regions on chro-
mosomes 14q, 9p-q, 10q, 18p-q, and 8q could contain
loci that are weakly linked to BPD in multiple popu-
lations. Because none of these findings achieved a ge-
nomewide level of significance on the basis of empirical
criteria, we do not review in detail the previous data
supporting these findings; most of these data are con-
tained in the genome scan studies that had the lowest
average ranks in these regions (figs. 1 and 2) and can
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be found in the referenced publications for these studies
and in other publications by these research groups.
One possible confounding factor here is that bins
18.2, 18.3, and 18.4 were tested with more markers per
bin than elsewhere in the genome—an average of 6.56
for bin 18.2 (the largest value in the genome), 4.78 for
bin 18.3, and 5.28 for bin 18.4. For model 3, there was
a Pearson correlation of 0.46 ( ) betweenP ! .00001
the average number of markers for the 120 bins and
their average ranks. Uniformly high marker density
would be an advantage, but, if some bins have much
higher marker density than average, a slightly higher
maximum linkage score tends to be observed within
them because of increased information content (recall
that lower scores are ignored), although the higher den-
sities observed here are not extreme in this regard (L.
Wise, unpublished data). GSMA could be further con-
founded if investigators who observed some evidence
for linkage in a candidate region then decided to in-
crease marker density. Low average ranks were not
noted for other regions with very high marker density
on chromosomes 5, 21, and 22. Marker density might
have contributed to our evidence for linkage on chro-
mosome 18 or might simply have been a response to
reports of linkage in this region.
There are many possible interpretations of our failure
to find genomewide significant evidence for linkage to
BPD. A general caveat is that, in complex disorders,
negative results do not disprove linkage; therefore, the
present study should not be interpreted as an absence
of genetic effects that might be detected by other meth-
ods—we tested only the hypothesis that GSMA could
detect loci that contributed to BPD susceptibility in
many of these diverse populations, through use of avail-
able samples.
It is possible that methodological factors contributed
to the negative results. On the broadest level, one might
consider the strengths and limitations of GSMA as a
method of meta-analysis. Whereas traditional meta-
analysis methods estimate an effect size from studies
that used the same methods and statistical tests, GSMA
is a nonparametric approach that tolerates a degree of
variability in sampling and statistical methods, yielding
largely empirically based measures of significance rather
than an effect size and localizing signals into relatively
broad bins (here, 30 cM in width). This flexibility of
GSMA is also a limitation, dictated by the limitations
of available genome scan data—it is possible that the
variability among BPD studies is impacting negatively
on the GSMA in undetected ways, and, indeed, in our
simulation studies we did not study the effects of some
of the decisions we made here, such as maximizing LOD
scores across two or more transmission models, marker
by marker, or including samples with diverse pedigree
sizes and structures. In most respects, however, there
was similar variability in the schizophrenia GSMA that
did produce genomewide significant results.
There are unresolved issues regarding the genetic ep-
idemiology of the spectrum of mood disorders that
could have influenced these results. A full review of these
issues is beyond the scope of this article, but we will
note several of them. The relative risk of BP-I disorder
in relatives of probands with BP-I versus the general
population has been estimated at 4–10 (Maier et al.
1993; Merikangas et al. 2002; Taylor et al. 2002). Rel-
ative risk appears to be elevated for probands with
younger age at onset (Todd 2002), but genome scans
have not focused on early-onset cases. There are con-
flicting data about differential risks depending on the
sex of the transmitting parent and/or of the proband
(McMahon et al. 1995; Gershon et al. 1996; Grigoroiu-
Serbanescu et al. 1998). There are a number of issues
regarding the differentiation between BP-I and BP-II dis-
orders. Although they are often combined in analyses,
it is possible that they are partially genetically distinct:
BP-II is more common in the relatives of probands with
BP-II than it is in the relatives of probands with BP-I
(Endicott et al. 1985; Heun and Maier 1993), one study
reported a greater relative risk for BP-II than for BP-I
(Heun and Maier 1993), and at least one linkage result
was observed primarily in families with BP-II–BP-II
ASPs (McMahon et al. 2001). Interrater reliability in
assessment of BP-II can be quite high (Simpson et al.
2002) but has typically been only fair (Rice et al. 1986;
Leboyer et al. 1991). The proportion of BP-I to BP-II
cases varies greatly across studies (table 1). Thus, dif-
ferences in approaches to diagnosing and analyzing
these two disorders may be a source of unmeasured
variability across linkage studies. Lastly, although major
depression is the most common disorder among the rel-
atives of probands with BPD, it is also common in the
population, and it has not been possible to distinguish
“bipolar” and “unipolar” depression on the basis of
clinical features and course (Blacker et al. 1996); there-
fore, BPD genome scans might be including genetically
heterogeneous cases of depression. Different and more
consistent approaches to some of these issues might
produce greater consistency in linkage findings across
studies.
Our negative results could also be due to the inter-
related problems of sample size, ethnic background,
and pedigree structure. A parsimonious interpretation
would be simply that power was inadequate. Only 347
pedigrees with BPD have been analyzed with a very
narrow model (model 1), versus ∼1,200 for schizo-
phrenia, for which the GSMA was more successful. If
there are differences in the genetic architecture of BP-I,
BP-II, and MDD in these families, then it is possible
that only analyses of much larger samples of narrowly
diagnosed cases will detect loci that influence BPD sus-
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ceptibility in many or most populations. Larger samples
are currently being collected or analyzed, so that this
hypothesis should be testable in the near future.
Alternatively, it is possible that BPD is characterized
by one or several types of substantial genetic hetero-
geneity—that is, major differences in the loci that un-
derlie susceptibility in different populations, the exis-
tence of multiple sets of interacting loci within each
population, and/or the existence of many different loci
that play major roles in susceptibility in a small pro-
portion of extended pedigrees. In each of these cases,
GSMA would be unlikely to have sufficient power. The
present analysis included three samples from unique
populations (Finland, Quebec, and the Central Valley
of Costa Rica), as well as samples comprised of highly
selected extended pedigrees (such as Columbia, Edin-
burgh, National Institute of Mental Health [NIMH]–
Intramural Program [IM], and University College [UC]
London) and others of smaller nuclear families. Al-
though the large schizophrenia GSMA was apparently
successful despite similar variability among samples, it
is possible that the genetics of BPD are sufficiently dif-
ferent to make a GSMA of all available scans a less
useful strategy. An additional limitation here is that X-
and Y-chromosome data are not currently accommo-
dated by the GSMA procedure.
There was little evidence to support an overlap be-
tween BPD and schizophrenia susceptibility regions, al-
though it is possible that such evidence will emerge as
the BPD data set increases. None of the cluster of
19 bins with in the schizophrenia analysisP ! .05ord
achieved even nominal significance in the BPD analysis.
It has been suggested that more information about pos-
sible BPD/schizophrenia overlap might be obtained with
linkage analysis of BPD data limited to subjects with
overt psychotic symptoms (hallucinations or delusions),
as well as with combined analyses of schizophrenia and
psychotic BPD data.
In summary, the GSMA of BPD represents an un-
biased exploration of evidence for common susceptibili-
ty genes for BPD. No chromosomal region produced
statistically significant results at the genomewide lev-
el. There were several promising results, including
for bin 9.2 (with in bin 9.3)P ! .01 P ! .05AvgRnk AvgRnk
and bin 10.3 for model 1 and for bin 14.3 for model
2. Nominally significant evidence for linkage was ob-
served for bins 14.3 and 18.2 under three different di-
agnostic models and for bin 8.6 under two models, as
well as for adjacent bins under some models. It would
appear that each BPD susceptibility gene might have a
small populationwide effect, thus requiring larger or
more refined samples to detect, and/or that locus het-
erogeneity across samples is considerable, and/or that
methodological problems in the meta-analysis or the
scan analyses themselves have limited the power of this
study. For complex disorders, an analysis of this type
is intended only to provide additional support for fur-
ther study of regions that provide evidence for linkage
across multiple scans. The results should not be inter-
preted as disconfirming findings of individual scans, and
there may be linkages that can be identified only in
specific pedigrees or populations. Finally, it is not at all
clear to what degree future studies using large collab-
orative samples versus samples of one or more extended
pedigrees will prove useful in finding and confirming
linkages. It would seem important that both strategies
be pursued.
We plan to update this analysis when several new
BPD genome scans are completed, and we invite inves-
tigators with new genome scan data to contact the pre-
sent authors.
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Appendix A
Summary of Terminology
Bin: One of 120 30-cM autosomal segments used as
units of analysis in GSMA; bin 2.1 is the first 30 cM of
chromosome 2.
Rstudy (within-study rank): The rank of each bin within
a single study, based on the maximum linkage score (or
lowest P value) within it. The bin containing the best
score has a rank of 1. All negative and 0 scores are
considered to be tied. For weighted analyses, each raw
rank is multiplied by the study’s weighting factor.
RAvg (average rank): The average of a bin’s within-
study ranks or weighted ranks across all studies.
PAvgRnk (probability of RAvg): The pointwise probability
of observing a given RAvg for a bin in a GSMA of N
studies, determined by theoretical distribution (un-
weighted analysis only) or by permutation test (fig. 2).
Pord (probability of RAvg given the order): The point-
wise probability that, for example, a first-place, second-
place, third-place, etc., bin would achieve RAvg at least
this extreme in a GSMA of N studies.
Genomewide significance: For , correctionap 0.05
for 120 bins yields a threshold for genomewide signifi-
cance of .000417 for PAvgRnk or Pord. For suggestive link-
age (a result observed once per scan by chance), ap
.1/120p 0.0083
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